Propentofylline
Title: Propentofylline
CAS Registry Number: 55242-55-2
CAS Name: 3,7-Dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1H-purine-2,6-dione
Additional Names: 3-methyl-1-(5-oxohexyl)-7-propylxanthine; 1-(5¢-oxohexyl)-3-methyl-7-propylxanthine
Manufacturers' Codes: HWA-285; Albert-285; HOE-285
Trademarks: Hextol (Hoechst); Karsivan (Provet)
Molecular Formula: C15H22N4O3
Molecular Weight: 306.36
Percent Composition: C 58.81%, H 7.24%, N 18.29%, O 15.67%
Literature References: Peripheral vasodilator which inhibits cyclic AMP phosphodiesterase. Prepn: W. Mohler et al., DE 2330742; eidem, US 4289776 (1975, 1981 both to Hoechst). Cardiovascular effects in animals: O. Hudlicka et al., Br. J. Pharmacol. 72, 723 (1981). Effect on cAMP phosphodiesterase: K. Nagata et al., Arzneim.-Forsch. 35, 1034 (1985). Inhibition of adenosine uptake: B. B. Fredholm, K. Lindström, Acta Pharmacol. Toxicol. 58, 187 (1986). Cerebrovascular effects in animals: J. J. Grome et al., Drug Dev. Res. 5, 111 (1985). Effect on postischemic brain edema: B. B. Mrsulja et al., ibid. 6, 339 (1985). Effect on cognitive function in humans: I. Hindmarch, Z. Subhan, ibid. 5, 379 (1985). Acute toxicity: M. Inazu et al., Oyo Yakuri 31, 357 (1986), C.A. 104, 218960a (1986).
Properties: Crystals from diisopropyl ether, mp 69-70°. Soly in water at 25°: 3.2%; in ethanol: >10%; in DMSO: >10%. LD50 in male, female mice, male, female rats (mg/kg): 900, 780, 1150, 940 orally; 168, 170, 180, 195 i.v.; 375, 346, 199, 196 i.p.; 450, 508, 400, 338 s.c. (Inazu).
Melting point: mp 69-70°
Toxicity data: LD50 in male, female mice, male, female rats (mg/kg): 900, 780, 1150, 940 orally; 168, 170, 180, 195 i.v.; 375, 346, 199, 196 i.p.; 450, 508, 400, 338 s.c. (Inazu)
Therap-Cat: Nootropic.
Therap-Cat-Vet: Vasodilator (peripheral and cerebral).
Keywords: Nootropic.

Others monographs:
AlaceprilCadmium CyanideIsoquassinChromonar
IrinotecanClonazepamClorsulonLactitol
p-DiaminoazobenzeneMifepristonePerfluoropropaneTrypan Blue
Manganese CarbonylKainic AcidMethyl Carbitol®Menthol
©2016 DrugLead US FDA&EMEA